Zobrazeno 1 - 10
of 2 178
pro vyhledávání: '"Once weekly"'
Autor:
Chrysoula Kosmeri, Maria Baltogianni, Vasileios Giapros, Ekaterini Siomou, Vasiliki-Regina Tsinopoulou, Foteini Balomenou, Anastasios Serbis
Publikováno v:
Endocrines, Vol 5, Iss 2, Pp 214-224 (2024)
Basal insulin analogs, typically administered once or twice daily, have been one of the two pillars of the multiple daily injection (MDI) insulin therapy of patients with type 1 diabetes (T1D) for the last twenty years. Recently, once-weekly basal in
Externí odkaz:
https://doaj.org/article/0b91297f66ed48269b92474422e11b72
Autor:
Syed Zia Saleem, Areeba Fareed, Syed Muhammad Muneeb Akhtar, Solay Farhat, Amira Mohamed Taha, Aymar Akilimali
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background//Objective Diabetes affects millions of people globally, despite treatment options, adherence and other factors pose obstacles. Once-weekly Insulin Icodec, a novel basal Insulin analog with a week-long half-life, offers potential
Externí odkaz:
https://doaj.org/article/227e67b1f27645f6a0779c38e6e92a10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sandro Augusto Goncalves Ribeiro, Matheus Pedrotti Chavez, Larissa Calixto Hespanhol, Caroline Cristine Almeida Balieiro, Eric Paqualotto, Rodrigo Ribeiro e Silva, Mateus Gauza, João Roberto de Sa
Publikováno v:
Metabolism Open, Vol 22, Iss , Pp 100285- (2024)
Background: Insulin icodec is a novel, long-acting, once-weekly basal insulin analog. Its comparative efficacy and safety with basal once-daily insulins in type 2 diabetes mellittus is uncertain. Objective: Evaluate potential efficacy, benefits and r
Externí odkaz:
https://doaj.org/article/80133e95cf3345318b1ea673e4cd9ec6
Autor:
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 an
Externí odkaz:
https://doaj.org/article/faf3645ed4d642638bc528022e510fa6
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 1943 (2024)
Background: Diabetes mellitus (DM) significantly impacts global health due to its complications and the economic burden it places on healthcare systems. The rise of novel once-weekly diabetes medications with different mechanisms of action necessitat
Externí odkaz:
https://doaj.org/article/ee3183a342fe4e298cd40cf09ccb88d0
Autor:
Giuseppe Lisco, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Edoardo Guastamacchia, Giuseppina Piazzolla, Olga Eugenia Disoteo, Vincenzo Triggiani
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1852 (2024)
Background. One hundred years have passed since the discovery of insulin, which is one of the most relevant events of the 20th century. This period resulted in extraordinary progress in the development of novel molecules to improve glucose control, s
Externí odkaz:
https://doaj.org/article/d9697670e97c4efebed3746d2fb5480b
Autor:
Irene Caballero Mateos, María Dolores García de Lucas, Viyey Kishore Doulatram-Gamgaram, Paloma Moreno-Moreno, Ana Isabel Jimenez-Millan, Manuel Botana-López, Juan Francisco Merino-Torres, Alfonso Soto-Gónzalez, José Carlos Fernández-García, Cristóbal Morales-Portillo
Publikováno v:
Nutrients, Vol 16, Iss 15, p 2545 (2024)
Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 d
Externí odkaz:
https://doaj.org/article/7d5ca37bfe7d48ebb3352731a5b23602
Autor:
Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri, Satesh Kumar
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractBackground The emergence of genetically-modified human proteins and glucagon-like peptide-1 (GLP-1) receptor agonists have presented a promising strategy for effectively managing diabetes. Due to the scarcity of clinical trials focusing on th
Externí odkaz:
https://doaj.org/article/579280376c3747b28641e632245ce960
Autor:
Roy Gomez, Roger Lamoureux, Diane M. Turner-Bowker, Jane Loftus, Mohamad Maghnie, Bradley S. Miller, Michel Polak, Andrew Yaworsky
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
IntroductionThe standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians’ preference f
Externí odkaz:
https://doaj.org/article/c25dfd24fe344bf4bef41ceea8b433db